Table 2.
Medication class | CKD stage 3A (eGFR 45–59 mL/min/1.73 m2), n/N=49/141 | CKD stage 3B (eGFR 30–44 mL/min/1.73 m2), n/N=52/141 | CKD stage 4/5 (eGFR 15–29 mL/min/1.73 m2), n/N=40/141 | Total combined medication use in CKD-MIT, N=141 | ||||
---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | n | % | |
Antihypertensive agent | 45 | 92 | 46 | 89 | 39 | 98 | 130 | 92 |
ACE inhibitor/ARB | 29 | 59 | 19 | 37 | 17 | 43 | 65 | 46 |
Diuretic | 21 | 43 | 31 | 60 | 31 | 78 | 83 | 59 |
Loop | 19 | 39 | 24 | 46 | 28 | 70 | 71 | 50 |
Thiazide | 4 | 8 | 6 | 12 | 6 | 15 | 16 | 11 |
Potassium sparing | 5 | 10 | 7 | 14 | 2 | 5 | 14 | 10 |
Beta blocker | 21 | 43 | 28 | 54 | 20 | 50 | 69 | 49 |
Calcium channel blocker | 13 | 27 | 13 | 25 | 18 | 45 | 44 | 31 |
Dihydropyridine | 7 | 14 | 9 | 17 | 16 | 40 | 32 | 23 |
Non-dihydropyridine | 6 | 12 | 5 | 10 | 3 | 8 | 14 | 10 |
Other antihypertensive | 0 | 0 | 7 | 14 | 6 | 15 | 13 | 9 |
Other OTC/herbal | 32 | 65 | 41 | 79 | 32 | 80 | 105 | 74 |
Platelet inhibitor | 35 | 71 | 31 | 60 | 23 | 58 | 89 | 63 |
Aspirin | 33 | 67 | 26 | 50 | 21 | 53 | 80 | 57 |
Other platelet inhibitor | 6 | 12 | 17 | 33 | 6 | 15 | 29 | 21 |
Statin | 29 | 59 | 35 | 67 | 22 | 55 | 86 | 61 |
Gastrointestinal agent | 27 | 55 | 29 | 56 | 21 | 53 | 77 | 55 |
Proton pump inhibitor (PPI) | 17 | 35 | 22 | 42 | 14 | 35 | 53 | 38 |
Other gastrointestinal agent | 17 | 35 | 15 | 29 | 10 | 25 | 42 | 30 |
Antihyperglycemic agent | 18 | 37 | 29 | 56 | 25 | 63 | 72 | 51 |
Insulin | 13 | 27 | 19 | 37 | 21 | 53 | 53 | 38 |
Oral antihyperglycemic agent | 10 | 20 | 16 | 31 | 6 | 15 | 32 | 23 |
Sulfonylurea | 4 | 8 | 7 | 14 | 5 | 13 | 16 | 11 |
Metformin | 7 | 14 | 6 | 12 | 1 | 3 | 14 | 10 |
DPP-4 Inhibitor | 2 | 4 | 2 | 4 | 0 | 0 | 4 | 3 |
Thiazolidinedione | 0 | 0 | 2 | 4 | 0 | 0 | 2 | 1 |
GLP-1 receptor agonist | 1 | 2 | 1 | 2 | 0 | 0 | 2 | 1 |
Vitamin D | 20 | 41 | 28 | 54 | 24 | 60 | 72 | 51 |
Psychoactive agents | 24 | 49 | 28 | 54 | 17 | 43 | 69 | 49 |
Antidepressant | 18 | 37 | 20 | 39 | 10 | 25 | 48 | 34 |
Anticonvulsant | 8 | 16 | 9 | 17 | 5 | 13 | 22 | 16 |
Anxiolytic | 8 | 16 | 4 | 8 | 5 | 13 | 17 | 12 |
Insomnia medication | 3 | 6 | 4 | 8 | 0 | 0 | 7 | 5 |
Other psychoactive agent | 1 | 2 | 0 | 0 | 0 | 0 | 1 | <1 |
Opioid agonist | 16 | 33 | 19 | 37 | 11 | 28 | 46 | 33 |
Acetaminophen | 13 | 27 | 21 | 40 | 10 | 25 | 44 | 31 |
Thyroid supplement | 13 | 27 | 13 | 25 | 11 | 28 | 37 | 26 |
Antibiotic agent | 15 | 31 | 10 | 19 | 11 | 28 | 36 | 26 |
Anticoagulant | 11 | 22 | 14 | 27 | 11 | 28 | 36 | 26 |
Warfarin | 9 | 18 | 11 | 21 | 10 | 25 | 30 | 21 |
Direct oral anticoagulant | 2 | 4 | 3 | 6 | 0 | 0 | 5 | 4 |
Heparin | 0 | 0 | 0 | 0 | 1 | 3 | 1 | <1 |
Low molecular weight heparin | 0 | 0 | 0 | 0 | 1 | 3 | 1 | <1 |
Uric acid lowering agent | 13 | 27 | 9 | 17 | 13 | 33 | 35 | 25 |
Iron supplements | 10 | 20 | 13 | 25 | 11 | 28 | 34 | 24 |
Nitrate | 10 | 20 | 13 | 25 | 7 | 18 | 30 | 21 |
Prescription phosphate binder | 0 | 0 | 2 | 4 | 3 | 8 | 12 | 9 |
Parkinson’s disease medication | 3 | 6 | 2 | 4 | 1 | 3 | 6 | 4 |
NSAID | 2 | 4 | 3 | 6 | 0 | 0 | 5 | 4 |
Erythropoietin stimulating agent | 0 | 0 | 1 | 2 | 1 | 3 | 2 | 1 |
Potassium binder | 0 | 0 | 1 | 2 | 0 | 0 | 1 | <1 |
Dementia medication | 0 | 0 | 1 | 2 | 0 | 0 | 1 | <1 |
Anti-neoplastic | 0 | 0 | 1 | 2 | 0 | 0 | 1 | <1 |
ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker; DPP-4: dipeptidyl peptidase-4; GLP-1: glucagon-like peptide-1; NSAID: nonsteroidal anti-inflammatory drug.